Vaccines Summaries
Lam, Woei Chuan ; Lodge, Jennifer ; Upadhya, Rajendra
T-014064
— Cryptococcus fungi are pathogenic fungi that, unless treated, are invariably fatal to those individuals infected, particularly to those who are immunocompromised. Recent reports indicate that Cryptococcus fungi infects 1,000,000 individuals per year and causes approximately 600,000 deaths. While ant…
Uropathogen VaccinesDodson, Karen ; Ellebedy, Ali ; Feldman, Mario ; Hultgren, Scott ; Pinkner, Jerome ; Tamadonfar, Kevin ; Timm, Morgan
T-020120
— Technology Description Researchers in Scott Hultgren’s laboratory at Washington University have created two prospective vaccine treatments designed to prevent the colonization of prominent uropathogens. These vaccines have potential for treating urinary tract infections (UTIs) with specific m…
Chimpanzee adenovirus-based vaccine for COVID-19Curiel, David ; Diamond, Michael ; Dmitriev, Igor ; Hassan, Ahmed
T-019478
— Technology Description Researchers at Washington University in St. Louis have developed a chimpanzee adenovirus-based vaccine for COVID-19. COVID-19, the clinical syndrome caused by SARS-CoV-2 infection, has had extensive morbidity and mortality impacts and destabilized society. There is an urg…
Recombinant VSV vector for COVID-19 vaccine or drug screeningRothlauf, Paul ; Whelan, Sean
T-019338
— Background: Recombinant vesicular stomatitis virus (VSV) has successfully been used to create a vaccine for Ebola virus that is currently on the market. Previously, Professor Sean Whelan and colleagues have exploited the VSV platform to create similar vectors for both SARS and MERS. Technology: The…
Target and method to treat alphavirus infectionsBasore, Katherine ; Diamond, Michael ; Fremont, Daved ; Kim, Arthur ; Nelson, Christopher ; Thackray, Larissa ; Zhang, Rong
T-017583
— Technology Description Researchers at Washington University in St. Louis have identified a target for therapeutic development and created methods to potentially treat arthritogenic alphavirus infection. Arthritogenic alphaviruses, including chikungunya (CHIKV), Ross River, Mayaro and O’nyong…
Vaccines and antibodies against malaria and other parasitic diseases in humans and animalsJimah, John ; Tolia, Niraj
T-016150
— Technology Description Researchers in Prof. Niraj Tolia’s laboratory have exploited structure-based vaccine design to develop immunogenic compositions and neutralizing antibodies that could protect against malaria and a range of other parasitic diseases that affect humans, livestock and comp…
Monoclonal Antibodies Against Zika Virus and Purified Zika E ProteinDiamond, Michael ; Fernandez, Estefania ; Fremont, Daved ; Nelson, Christopher ; Platt, Derek ; Zhao, Haiyan
T-016168
— To generate a panel of antibodies against ZIKV, we serially infected Irf3/ mice 30 days apart with ZIKV MR-766 (Uganda, 1947) and ZIKV H/PF/2013 (French Polynesia, 2013). Irf3/ mice were used instead of wild-type (WT) mice, because ZIKV strains are deficient in evading type I interferon-mediated imm…
Vaccine to prevent catheter-associated urinary tract infectionCaparon, Michael ; Flores-Mireles, Ana ; Hultgren, Scott ; Pinkner, Jerome
T-013965
— Technology Description Researchers at Washington University in St. Louis have developed a vaccine strategy to prevent catheter-associated urinary tract infections (CAUTIs). CAUTIs are the most common cause of hospital-acquired infections. Many of these are caused by Enterococcus bacteria. CAUTIs a…
Engineered Adenovirus Vector for Efficient Dendritic Cell Antigen Loading in Cancer ImmunotherapyCuriel, David
T-011681
— Disease indication – Cancer Drug format – Adenoviral vector for immunotherapy/dendritic cell therapy Drug class – Improvement Research stage and Preliminary data: Target – Carbohydrate biomarkers of cancer Background: Dendritic cells (DCs) are potent antigen presenting cell…
geOMV: Bacterial vaccine development platform using glycoengineered microbesFeldman, Mario
T-015094
— Technology Description Researchers in Prof. Mario Feldman’s laboratory have developed a patented, versatile, cost-effective platform for creating new multivalent vaccines for a variety of Gram-negative and Gram-positive bacteria. This technology, glycoengineered outer membrane vesicles (geOM…
Novel human astrovirus sequences for diagnostics and vaccine development for encephalitis and gastroenteritisFinkbeiner, Stacy ; Virgin, Herbert ; Wang, David ; Zhao, Guoyan
T-009294
— Technology Description A team of researchers at Washington University and the Centers for Disease Control discovered, sequenced and patented a novel human astrovirus that can cause encephalitis and gastroenteritis (non-etiologic diarrhea), offering a path to detection and diagnostics. The virus (…
Chimpanzee adenovirus-based vaccine for COVID-19Curiel, David ; Diamond, Michael ; Dmitriev, Igor ; Hassan, Ahmed
T-019478
— Technology Description Researchers at Washington University in St. Louis have developed a chimpanzee adenovirus-based vaccine for COVID-19. COVID-19, the clinical syndrome caused by SARS-CoV-2 infection, has had extensive morbidity and mortality impacts and destabilized society. There is an urg…
Recombinant VSV vector for COVID-19 vaccine or drug screeningRothlauf, Paul ; Whelan, Sean
T-019338
— Background: Recombinant vesicular stomatitis virus (VSV) has successfully been used to create a vaccine for Ebola virus that is currently on the market. Previously, Professor Sean Whelan and colleagues have exploited the VSV platform to create similar vectors for both SARS and MERS. Technology: The…
